XERSXeris Biopharma Holdings, Inc.vs its industry peers
A metric-by-metric comparison of Xeris Biopharma Holdings, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XERSThis | $1.4B#8 | — | — | 4.9x#4 | 43.7%#3 | 101.0%#2 | 8.5%#4 | — | 20.6%#1 | — | 4.4%#12 | — |
| ANAB | $1.6B#1 | — | 124.0x#13 | 6.7x#5 | 157.0%#2 | 90.9%#4 | 20.4%#2 | -103.8%#12 | — | — | 180.0%#4 | — |
| SNDX | $1.5B#2 | — | 102.1x#12 | 8.9x#6 | 627.8%#1 | 10.5%#7 | -158.4%#6 | -1890.2%#13 | -1205.8%#6 | — | 14.9%#10 | — |
| AVLN | $1.5B#3 | — | 3.9x#7 | — | — | — | — | 0.0%#2 | — | — | — | — |
| INVA | $1.5B#4 | 4.9x#3 | 1.2x#1 | 3.7x#2 | 14.7%#6 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#2 | 5#2 | 9.8%#11 | — |
| DMRA | $1.5B#5 | 3.2x#2 | 2.9x#3 | — | — | -878.8%#13 | — | -40.7%#10 | — | — | 751.8%#2 | — |
| BCAX | $1.5B#6 | — | 3.1x#4 | — | — | -102.9%#11 | — | -29.4%#6 | — | — | 95.6%#7 | — |
| TYRA | $1.5B#7 | — | 4.1x#8 | — | — | -38.7%#10 | — | -33.9%#8 | — | — | 96.4%#6 | — |
| TRAX | $1.4B#9 | — | 8.3x#10 | — | — | — | — | 0.0%#2 | — | — | — | — |
| LBRX | $1.4B#10 | 1.9x#1 | 4.1x#9 | — | — | 60.1%#6 | — | -7.6%#5 | — | — | 170.5%#5 | — |
| AVBP | $1.4B#11 | — | 3.7x#6 | — | — | -106.6%#12 | — | -45.3%#11 | — | — | 52.3%#8 | — |
| ORIC | $1.3B#12 | — | 3.4x#5 | — | — | -1.3%#9 | — | -34.0%#9 | -40.4%#4 | — | 15.1%#9 | — |
| HROW | $1.3B#13 | — | 84.4x#11 | 4.7x#3 | 36.4%#4 | 70.6%#5 | 11.2%#3 | -33.8%#7 | 13.2%#3 | 6#1 | -20.2%#13 | — |
| RARE | $1.3B#14 | — | — | 1.9x#1 | 20.2%#5 | -1.1%#8 | -79.5%#5 | — | — | — | -56.3%#14 | — |
| OMER | $1.3B#15 | 10.0x#4 | — | 17.0x#7 | -34.0%#7 | 97.9%#3 | -166.4%#7 | — | -151.8%#5 | — | 328.7%#3 | — |
| AKTS | $1.2B#16 | — | 2.5x#2 | — | — | — | — | 0.0%#2 | — | — | 23319.4%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice